Telcon at 5:30 p.m. ET Today MOUNTAIN VIEW, Calif., Feb. 23 (HSMN NewsFeed) — MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) announced today results of its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment o…
Biopharmaceuticals
MAP Pharmaceuticals, AstraZeneca, Budesonide, asthma

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints”
Leave a Comment